PledPharma Readies PledOx For Phase III FDA Talks And Partnering

PledPharma unveiled potentially transforming Phase IIb top-line results for its new medicine PledOx, which aims to reduce severe side effects from chemotherapy. The Swedish small cap firm now will engage with regulators to map out its Phase III program – and woo potential commercial partners for the needed financing.